anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with head and neck cancer and undergo neck dissection often suffer from spinal accessory nerve dysfunction (e.g. shoulder droop, shoulder pain, and decreased active range of motion (AROM) of the shoulder joint and scapular muscle strength), even the spinal accessory nerve is preserved during surgery. Abnormal muscle activities of scapular muscles, including upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), serratus anterior (SA) and rhomboid were reported in subsequent research articles. Particularly for the trapezius muscle, the decreased amplitudes were observed even after 9 months of neck dissection. It has been reported that conscious correction of scapular orientation during arm movement could increase trapezius muscle activities, and motor control training could change scapular kinematic such as increased posterior tilt and upward rotation during arm movement.

The aim of this study is to explore the effects of electromyographic (EMG) visual feedback on scapular muscle activities and strength in oral cancer survivors with spinal accessory nerve dysfunction. Investigators will recruit 60 newly diagnosed oral cancer subjects through the plastic surgeon's referral from January 2020 to February 2021. The participants will be randomized separated into experimental or control group. Each group would receive regular physical therapy for shoulder function (e.g. transcutaneous electrical stimulation, shoulder joint range of motion exercise) and scapular-focused exercise. EMG visual feedback would be combined with scapular-focused exercise.
This invention relates to a novel anti-cancer drug-3,6-di(2-hydroxy-5-chlorophenyl)-5-tetrazine and transtion metal coordination compound, its prepn. method, and its application. Experiment shows that, this coordination compound of said terazine and transition metal has obvious anti-cancer activity. This invention prepn. of coordination compound is of simple process. This invention can help to select new medicines.
Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
In the control group, stereotactic body radiotherapy (SBRT) alone is performed. SBRT is administered three times, at intervals of 1-2 days. The scattered dose should not exceed EQD2 2Gy to the non-irradiated lesion.
Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.
This study investigates the relationship among maternal secretor status, human milk oligosaccharides (HMOs), and the composition of breastmilk microbiota in a cohort of healthy mothers from Shaanxi province, China. The results demonstrated that 78.9% of the mothers were secretors, exhibiting an active fucosyltransferase 2 gene (fut2) and producing α-1,2 fucosylated HMOs, which significantly affected the HMO profile. Secretor mothers had higher levels of 2'-FL and LNFPI in contrast to nonsecretors who displayed high levels of 3'-FL, LNFPII, and LNT. Furthermore, secretor mothers exhibited greater diversity in HMOs compared with nonsecretors, although no significant differences were observed in the breast milk microbiota composition. A correlation was identified between specific HMOs (2'-FL, 3'-FL, 6'-SL, and LNFPI) and the microbiota composition. Notably, mothers with normal weight gain during pregnancy demonstrated higher microbial diversity, with increased abundance of beneficial genera such as Bifidobacterium, Lactobacillus, and Ligilactobacillus. These findings contribute to the development of potential guidelines for providing personalized nutrition.
Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization.

The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear.

To report SUSPECTED ADVERSE REACTIONS, contact Casper Pharma LLC. at 1-844-5-CASPER (1-844-522-7737) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
FIELD: medicine and pharmaceutical composition. SUBSTANCE: described are new macrocyclic bis-indolemaleimide derivatives of formula I:   wherein R 1 ,R 2 ,X,Y,W,m are as defined in claim 1. They relate to new and potent proteinkinase C inhibitors and have high isosime selectivity. They are useful in treating diseases associated with diabetes and also diseases such as ischemia, skin diseases and cancer. Also described are method of preparation thereof (variants) and pharmaceutical composition based on compounds of formula I. EFFECT: improved properties of the title composition. 15 cl, 121 ex, 2 tbl
The invention provides an intelligent transfer queuing method and device. Relates to the technical field of internet. The intelligent transfer queuing method comprises the following steps: and if the current number of the number-taking of the target window exceeds a preset threshold value, determining whether a target client meeting the transfer condition exists in the waiting queue of the target window according to the client number-taking information in the waiting queue of the target window and the client number-taking information in the waiting queue of the alternative window. Wherein the service content of the alternative window comprises the service request content of the target client. And if the target window waiting queue has the target clients meeting the transfer conditions, transferring the target clients to the alternative window waiting queue. The intelligent transfer queuing method can realize that the client who queues first transacts the business first, and can share the pressure of the target window, and has the advantage of transacting the business for more clients in the same time period.
In a method of controlling satiety a food product comprising a satiety controlling amount of a food additive, which consists of a triacylglycerol or a mixture of triacylglycerols, and an emulsifier is provided to a person. Acyl is tetradecanoyl to eicosanoyl, optionally mono- or di-unsaturated, optionally alpha-monosubstituted with saturated C 1 -C 4  alkyl. More than 15 mole-% of total acyl is comprised by alpha-substituted acyl. The person is directed to consume the food product from 1 h to 8 h prior to a meal. Thereby the amount of food consumed in the meal is reduced in comparison with the amount of food consumed in a corresponding meal following, by a corresponding time difference, the consumption of a food product of equal energy content but lacking the additive. Also disclosed are corresponding additives and compositions comprising them, and their use.
In the Smoking group, the HFNC was performed after the patient lost spontaneous breathing until the end-tidal oxygen concentration reached 95 %. record the patient 's safe apnea time.
200 Patients will be identified through routine daily scanning of imaging records (CT, Echocardiography) for patients diagnosed with PE. Presenting signs and symptoms as well as clinical and imaging findings during the initial presentation and hospitalization will be incorporated into a computerized pre-specified electronic CRF. During hospitalization, an endothelial function test will be performed 48 hours post admission. A trained technician will perform the test using the EndoPAT device in order to assess patient RHI, a score less than 1.67 will be considerate as endothelial dysfunction. Patients will then be followed for pre-specified clinical events of up to 1 year post discharge and especially the development of chronic thromboembolic pulmonary disease, post thrombotic syndrome and clinical events. RHI will be assessed during 1-year follow up visit.
Develop and test the non-inferiority of a new RT prescription model, entitled The Autonomy and Perceptions Approach to Resistance Training (APART). This approach is simple to follow, individualized, and autonomy supportive. Accordingly, it may assist trainees to overcome some of the limitations of the standard RT prescription approach. Under APART, trainees choose the loads they lift for each exercise according to their preferences, and then complete as many repetitions as required until reaching a specific rating of perceived effort (RPE) value on a 0 (no effort) to 10 (maximal effort) scale (e.g., 8/10). For this non-inferiority randomized controlled trial, the investigators will recruit 120 healthy, sedentary participants, between the ages of 18 and 45, who will be block-randomized by gender and age (18-27, 28-45) to either the APART or the standard groups. Following two baseline-testing sessions and two guided familiarization sessions, participants will independently complete three RT sessions per week for 12 weeks. The following primary outcomes will be assessed after six and 12 weeks: (ⅰ) body composition including fat free mass; (ⅱ) performance measures, including maximal strength and strength endurance; and (ⅲ) physiological measures, including blood profile and hemodynamics. The following secondary outcomes will be measured every two weeks: (ⅳ) psychological measures, including self-efficacy, autonomy, and enjoyment; and (ⅴ) adherence measures, which will be monitored throughout the intervention. If APART will be found to be non-inferior to the standard RT prescription, it can provide a simple and easy to follow alternative to the standard RT prescriptions, which also highlights trainees' preferences and individual abilities. This, in turn, might contribute to future participation and adherence to RT.
An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.
Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
PURPOSE: Skin moisturizer comprising abalone extracts is provided to have antioxidant activity and an ability to produce collagen and prevent the effect of MMP-1(matrix metalloproteinase). CONSTITUTION: A method of fermenting abalone extracts comprises the following steps: Abalone meat and pulverized abalone inner organs are mixed with water and vaccinated with lactobacillus and yeast. Fermented extracts are aged. The lactobacillus is selected from Lactobacillus sakei, Lactobacillus brevis, Lactobacillus plantarum, Lactococcus Lactis, Bacillus coagulance, and a mixed group comprising the same. The yeast is Bacillus subtilis. The moisturizer composition comprises 0.001-80 wt% of the abalone fermented extract based on the whole composition.
The invention discloses a compound medicine composition for treating anaphylactic rhinitis. A preparation formulation of the compound medicine composition is oral pellicles. The formulation of the compound medicine composition mainly comprises effective ingredients as follows: desloratadine, zinc gluconate, a film-forming material, a filling agent, a plasticizer and a sweetening agent. A preparation method is simple and comprises the following steps of (1) weighing raw materials and auxiliary materials as follows: the desloratadine, the zinc gluconate, the film-forming material, the filling agent, the plasticizer, the sweetening agent and the like; (2) wetting the desloratadine by using the plasticizer, mixing the zinc gluconate, the film-forming material, the filling agent, the plasticizer and the sweetening agent in the desloratadine, adding solvent water in the mixture, uniformly stirring the mixture and standing; (3) adding appropriate essence and a color enhancing agent in the mixture after the mixture is swelled completely, uniformly stirring the mixture and standing for a period of time; and (4) coating the mixture and drying the mixture to obtain the compound medicine composition. The compound medicine composition for treating the anaphylactic rhinitis tastes good, a patient does not need to drink water when orally taking the compound medicine composition, and medication compliance of the patient is improved; and the compound medicine composition can be dissolved quickly in the oral cavity of the patient, parts of medicines can be absorbed by oral mucosa of the patient, and a first-pass effect and gastrointestinal tract side effects are avoided to a certain degree. Moreover, the preparation method of the compound oral water-soluble film is simple, consumed time is short, and the cost is low.
PURPOSE:To provide a carcinostatic agent containing a polyisoprenyl monophosphate compound as an active component. CONSTITUTION:The objective carcinostatic agent contains the compound of formula (R is 40-110 polyprenyl; M is H or cation) as an active component. It can be administered by topical application, oral administration, injection, etc. at a dose of 10mg-2g/kg daily for oral administration and 4mg-1g/kg daily for parenteral administration, in the form of tablet, granules, or powder in the case of oral administration. Especially, granules and powder can be encapsulated to enable the administration of the unit dose. The compound of formula used as an active component can be prepared by phosphatizing an alpha-unsaturated polyisoprenol with ditriethylamine phosphate or an alpha-saturated polyisoprenol with phosphorus oxychloride, and separating and purifying the produced compound from the reaction mixture.
This is a Phase 1 randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers who are Human Immunodeficiency Virus-1 (HIV-1) uninfected. Participants in the study will receive 4 injections at 0, 4, 8 and 24 weeks and will be followed for an additional 24 weeks. The total study duration will be 48 weeks. As this is a Phase 1 trial, the primary objective is to document safety of the Full Length Single Chain (FLSC) gp120-CD4 complex vaccine with a secondary objective to evaluate immune responses induced by the vaccine. This vaccine is being evaluated as it is constructed so that the gp120 and CD4 moieties form a stable intra-chain binding interaction that forms a transition state structure that presents conserved, conformational domains involved in the early HIV replication process. It is hypothesized that antibodies directed to these epitopes would be highly cross-reactive and potentially useful for HIV vaccine development.
Background: Recurrent Acute Pancreatitis (RAP) is occurrence of 2 or more distinct episodes of Acute Pancreatitis (AP) (separated by at least 3 months). RAP not only leads to significant morbidity and reduced quality of life; patients with RAP have a substantial (up to 40%) risk of progressing to chronic pancreatitis (CP). Unfortunately, there is no therapy, which can help prevent future attacks of pancreatitis in RAP patients. In this regard, our published work suggest that pirfenidone, a therapy approved by FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF), has the potential to emerge as a novel treatment for patients with RAP. Briefly, our results suggest that: 1) Pirfenidone, when administered prophylactically, reduces the risk of AP development; 2) Pirfenidone, when given to experimental animals with severe AP, leads to amelioration of local and systemic injury; and 3) Pirfenidone, when administered to experimental animals with ongoing RAP, reduces risk of progression to CP. Thus, our results suggest that pirfenidone has potential to emerge as novel therapeutic strategy for RAP patients. These studies have high translational value as pirfenidone is already in clinical use for IPF and has over 8 years of record of safety.

Hypothesis: "Pirfenidone treatment in patients with RAP will be safe, tolerable, and efficacious." Objectives: The study has following primary and secondary objectives. Primary Objective: 1) To evaluate the safety and tolerability of pirfenidone compared to placebo, in patients with RAP. 2) To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation.

Secondary Objective: 1) To evaluate the efficacy of pirfenidone in reducing- a) recurrence of AP; b) pancreatitis related emergency room visits and readmissions; c) severity of pancreatitis, if acute pancreatitis was to develop; d) Improving quality of life measures; e) Improvement in patient reported outcomes. 2) To develop a predictive biomarker of efficacy of pirfenidone, which can be incorporated in a future clinical trial.

Specific aims and study design. Pilot Clinical Trial of the Safety, Tolerability and Efficacy of Pirfenidone in RAP. We will conduct a randomized, double-blind, placebo controlled pilot trial of pirfenidone in patients with RAP. RAP patients, 18-85 years of age who meet the eligibility criteria, will be recruited at one of the three participating sites (UAB, Mayo clinic Rochester and Brigham and Women's Hospital, Boston), and randomly assigned to pirfenidone or placebo treatment for 6 months. The primary endpoints of this clinical trial are a) feasibility; and b) safety. We have multiple efficacy secondary endpoints endpoint like cumulative incidence and rate of recurrent attacks of AP, severity of recurrent attacks of AP (mild/moderate/severe), readmissions and/or ER visits for pain, changes in quality of life as measured by PANQOLI and SF-12 health survey questionnaires, and changes in changes in patient reported outcome as measured by PAN-PROMISE score. We plan to recruit 60 patients at the three study sites over the duration of this clinical trial.
Clinical efficacy was evaluated in two randomized, double-masked, vehicle-controlled U.S. trials in which subjects with a summed ocular inflammation score ≥3 after cataract surgery were assigned to bromfenac ophthalmic solution or vehicle in a 2:1 ratio following surgery. One drop of bromfenac ophthalmic solution or vehicle was self-instilled in the study eye twice a day for 14 days, beginning the day after surgery. The primary endpoint was reduction of ocular inflammation (to trace inflammation or clearing) assessed 14 days post-surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant effect of bromfenac ophthalmic solution on ocular inflammation after cataract surgery was demonstrated (62 to 66% vs. 40 to 48%). An additional efficacy end point was the time required for resolution of ocular pain in subjects who reported pain. Overall, only 20% of the patients undergoing cataract surgery in these trials had pain on the first day after surgery. In these patients, the bromfenac ophthalmic solution group demonstrated a statistically significant difference in median time to resolution of ocular pain of 2 days compared to 4 days for patients receiving vehicle.
The present invention relates to a medical information processing system, a medical information processing method, and a storage medium, which are capable of diagnosing and treating a patient without being affected by instability of an answer to an inquiry. A medical information processing system according to an embodiment includes an acquisition unit, an estimation unit, and an output control unit. The acquisition unit acquires examination data indicating a medical examination result for a patient to be examined and answer data indicating an answer result to an inquiry of the patient to be examined. The estimation unit estimates information related to medical treatment of the medical treatment target person by inputting the examination data of the medical treatment target person to the 1 st model. Further, the estimation unit estimates information related to the medical treatment of the medical treatment target person by inputting the examination data and the answer data of the medical treatment target person to the 2 nd model. The output control unit outputs a 1 st estimation result of the 1 st model and a 2 nd estimation result of the 2 nd model via an output unit.
FIELD: biotechnology, medicine, pharmaceutical technology. SUBSTANCE: invention relates to technology of preparing medicinal forms of recombinant proteins. In the process of preparing liquid form of corresponding recombinant protein an effective amount of the latter is dissolved in biocompatible buffer solution containing nonionic detergent and, in some cases, stabilizing agent additionally. For preparing the medicinal form buffer solution with pH value distinguishing by more 1 unit from isoelectric point of protein is used. This provides stable state of protein at low concentrations (1- 100 mcg/ml) in solutions without aggregation and oligomerization. Tween-20, Tween-80, Tween-60, Nonidet P-40 and others can be used as detergent. Isotonic buffer solutions based on citrate, acetate, phosphate and others can be used as biocompatible buffer systems. In some cases for correction of osmomolarity solutions can contain polyatomic alcohols, dextrins, polyvinylpyrrolidones and others biocompatible polymeric components as stabilizing agent. EFFECT: decreased cost, safety of preparation. 4 cl, 4 tbl, 3 dwg